Mar 19, 2007 . Progression-free survival (PFS) is a term that is used to describe treatment results

Progression-free survival may be used in a clinical study or trial to help find out

Progression-free survival in gastrointestinal stromal tumours with high-dose

The length of time during and after treatment in which a patient is living with a

Nov 30, 2011 . Combination treatment with everolimus, an inhibitor of the mammalian target

Jan 11, 2012 . The investigational drug tivozanib demonstrated superiority over sorafenib (

October 26, 2011 — A phase 2b study has found that adding TG4010, a new

Dec 29, 2011 . Targeted drugs, which block or disrupt particular molecules involved in the

Published online before print February 27, 2012, doi: 10.1200/JCO.2011.38.7571

When is Progression-Free Survival an Important Clinical Trial Endpoint? Monday,

uses 6-month progression-free survival (6moPFS) as the efficacy end point of

Nov 29, 2011 . Combination Treatment with Octreotide Shows Improved Results in Tumors

Here we cite our concerns with the use of Progression Free Survival (PFS) as the

Oct 22, 2011 . An experimental vaccine, called TG4010, given together with chemotherapy

Feb 10, 2012 . Combination treatment with everolimus and the aromatase inhibitor exemestane

J Cancer 2012; 3:7-13. doi:10.7150/jca.3.7. Research Paper. Progression-free

Dec 29, 2011 . Along with results from the OCEANS trial presented at the 2011 ASCO meeting,

Oct 18, 2011 . Progression-free survival (PFS) is frequently used as a primary end point in

ung cancer patients given amrubicin (Calsed) as a second-line treatment had a

The North American Brain Tumor Consortium (NABTC) uses 6-month

Amit Oza, V. Castonguay, D. Tsoref, I. Diaz–Padilla, K. Karakasis, H. Mackay, S.

Its aim was to identify the factors which influence progression -free survival (PFS)

Nov 22, 2011 . Though the combined therapy improved progression-free survival (PFS) by 5

Jan 1, 2012 . Analysis of the 1236C>T SNP revealed a significant association with progression

Two drugs presented Wednesday at the San Antonio Breast Cancer Symposium

Mcl-1 expression predicts progression-free survival in chronic lymphocytic

Jan 26, 2012 . Erlotinib has been shown to improve progression-free survival compared . The

Evaluation of progression-free survival by blinded independent central review in

“Olaparib significantly prolonged progression-free survival by nearly 4 months on

of a given therapy may be since information on progression-free and overall

Dec 14, 2011 . Progression-free survival improved in patients with advanced neuroendocrine

Avastin plus IFN improved median PFS by 89% vs placebo plus IFN in AVOREN.

Dec 7, 2011 . Progression-free survival (PFS) was 18.5 months for patients who received

HOUSTON - In an international Phase III randomized study, an inhibitor of the

In a randomised phase 3 trial, panitumumab significantly improved progression-

Mar 19, 2012 . PRESS RELEASE: Pazopanib improves progression free survival in adults with

The median duration of remission and the median progression-free survival in

Continuing pemetrexed (Alimta) as maintenance therapy after its use as part of a

Progression-free survival (PFS) is the length of time during and after medication

Jun 4, 2011 . At the American Society of Clinical Oncology's 2011 Annual Meeting, results of

Progression-Free Survival and Overall. Survival in Oncology Studies. ABSTRACT

Jul 14, 2011 . Second, one justification given for using progression-free survival as the . Fourth

Compared with a placebo, treatment with the oral, targeted drug Votrient® (

Feb 9, 2011 . Novartis drug Afinitor® extends progression-free survival in patients with

Dec 6, 2011 . Dr. Mario Campone defines progression free survival (PFS) in relation to

Oct 13, 2011 . Should this progression-free survival “in the absence of an overall survival

Jun 1, 2011 . First cancer vaccine to show improved response rate.

Oct 9, 2010 . For patients with advanced lung cancer whose tumors carry EGFR activating

Feb 27, 2012 . Programmed cell death 6 (PDCD6) beside its known proapoptotic functions may

Feb 6, 2012 . First-line treatment with sunitinib for 9 months or more may be associated with a

Sitemap